Management of Acute Myeloid Leukemia with Respiratory Complications

Diagnosis and Assessment

• The European Hematology Association recommends checking white blood cell count immediately in patients with suspected acute myeloid leukemia, as hyperleukocytosis (WBC >100 × 10⁹/L) suggests leukostasis, which causes microvascular occlusion in lungs and brain 1, 2

Urgent Interventions

• The American Society of Clinical Oncology suggests performing leukapheresis before chemotherapy in patients with WBC >100 × 10⁹/L presenting with respiratory symptoms, as this procedure may reduce early mortality from leukostasis 1, 3, 4
• The National Comprehensive Cancer Network recommends initiating chemotherapy without delay in patients with hyperleukocytosis and respiratory symptoms, as cytoreduction is the definitive treatment 1, 3, 4

Supportive Care

• The European Society for Medical Oncology recommends maintaining platelet count >10 × 10⁹/L with prophylactic transfusions, and increasing the threshold to >20 × 10⁹/L if fever or infection is present 1, 2
• The American Society of Hematology suggests avoiding aggressive red cell transfusion in hyperleukocytosis, as increasing blood viscosity may worsen leukostasis 6

Special Considerations

• The International Society on Thrombosis and Haemostasis recommends starting ATRA 45 mg/m²/day immediately without waiting for genetic confirmation if acute promyelocytic leukemia is suspected, and adding chemotherapy immediately if WBC >10 × 10⁹/L to prevent differentiation syndrome 6, 7, 8